Differential Impact of the Neutrophil-Lymphocyte Ratio on the Survival of Patients with Stage IV Gastric Cancer

2014 ◽  
Vol 31 (4-5) ◽  
pp. 327-333 ◽  
Author(s):  
Hiroaki Tanaka ◽  
Kazuya Muguruma ◽  
Takahiro Toyokawa ◽  
Naoshi Kubo ◽  
Masaichi Ohira ◽  
...  
BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Naohiko Nakamura ◽  
Shinichi Kinami ◽  
Yasuto Tomita ◽  
Takashi Miyata ◽  
Hideto Fujita ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-6
Author(s):  
Wei Ge ◽  
Li-ming Zheng ◽  
Gang Chen

To assess whether preoperative markers could predict the stage of patients with gastric cancer. We analyzed retrospectively the preoperative indicators between stage IV and non-stage IV gastric cancer at the Gastrointestinal Surgery of Nanjing Drum Tower Hospital. A total of 500 patients with gastric cancer were screened. Of all the variables, alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125, carbohydrate antigen (CA) 199, carbohydrate antigen (CA) 724, carbohydrate antigen (CA) 242, thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT), blood platelet count (PLT), white blood cell (WBC) count, C-reactive protein (CRP), neutrophil count (NC), lymphocyte count (LC), neutrophil-lymphocyte ratio (NLR), hemoglobin (HB), aspartate aminotransferase (AST), and ascites were found to have statistical differences between the two groups. Then, Stepwise Discriminant Analysis was conducted to establish a prediction model including 7 indexes (CA724, CA242, TT, PLT, CRP, AST, and ascites). According to the model, 90.6% of original grouped cases were correctly classified and 90.6% of cross-validated grouped cases were correctly classified. We built a discriminant including CA724, CA242, TT, PLT, CRP, AST, and ascites for predicting patients with gastric cancer to be either stage IV or non-stage IV. According to this discriminant, 90.6% of patients could be correctly predicted.


2016 ◽  
Vol 25 (1) ◽  
pp. 87-94 ◽  
Author(s):  
Kunihiko Izuishi ◽  
Hirohito Mori

Recently, many strategies have been reported for the effective treatment of gastric cancer. However, the strategy for treating stage IV gastric cancer remains controversial. Conducting a prospective phase III study in stage IV cancer patients is difficult because of heterogeneous performance status, age, and degree of cancer metastasis or extension. Due to poor prognosis, the variance in physical status, and severe symptoms, it is important to determine the optimal strategy for treating each individual stage IV patient. In the past decade, many reports have addressed topics related to stage IV gastric cancer: the 7th Union for International Cancer Control (UICC) TNM staging system has altered its stage IV classification; new chemotherapy regimens have been developed through the randomized ECF for advanced and locally advanced esophagogastric cancer (REAL)-II, S-1 plus cisplatin versus S-1 in RCT in the treatment for stomach cancer (SPIRITS), trastuzumab for gastric cancer (ToGA), ramucirumab monotherapy for previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD), and ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW) trials; and the survival efficacy of palliative gastrectomy has been denied by the reductive gastrectomy for advanced tumor in three Asian countries (REGATTA) trial. Current strategies for treating stage IV patients can be roughly divided into the following five categories: palliative gastrectomy, chemotherapy, radiotherapy, gastric stent, or bypass. In this article, we review recent publications and guidelines along with above categories in the light of individual symptoms and prognosis. Abbreviations: APC: argon plasma coagulation; AVAGAST: anti-angiogenic antibody bevacizumab, the avastin in gastric cancer; BSC: best supportive care; CF: cisplatin and fluorouracil; CRP: C-reactive protein; DCF: docetaxel, cisplatin, and 5-FU; FISH: fluorescent in-situ hybridization; GJ: gastrojejunostomy; GPS: Glasgow Prognostic Score; HER: human epidermal growth factor receptor; HR: hazard ratio; NLR: neutrophil-to-lymphocyte ratio; OS: overall survival; PS: performance status; QOL: quality of life; RAINBOW: ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma; RCTs: randomized controlled trials; REAL: randomized ECF for advanced and locally advanced esophagogastric cancer; REGARD: ramucirumab monotherapy for previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma; REGATTA: reductive gastrectomy for advanced tumor in three Asian countries; SEER: Surveillance Epidemiology and End Results; SEMS: self-expandable metal stents; SPIRITS: S-1 plus cisplatin versus S-1 in RCT in the treatment for stomach cancer; ToGA: trastuzumab for gastric cancer; TTP: time-to-progression; VEGFR: vascular endothelial growth factor receptor.


Author(s):  
Yuji Toyota ◽  
Kunio Okamoto ◽  
Norimitsu Tanaka ◽  
Hugh Shunsuke Colvin ◽  
Yuta Takahashi ◽  
...  

2013 ◽  
Vol 37 (7) ◽  
pp. 1681-1687
Author(s):  
Naoshi Kubo ◽  
Masaichi Ohira ◽  
Katsunobu Sakurai ◽  
Takahiro Toyokawa ◽  
Hiroaki Tanaka ◽  
...  

2014 ◽  
Vol 50 ◽  
pp. e49
Author(s):  
R. Eghdam Zamiri ◽  
M. Moghimi ◽  
A. Yaghoobi Gooybari ◽  
S. Keyhanian ◽  
S. Mazloomzadeh ◽  
...  

2005 ◽  
Vol 30 (1) ◽  
pp. 21-27 ◽  
Author(s):  
Reza F. Saidi ◽  
Stephen G. ReMine ◽  
Paul S. Dudrick ◽  
Nader N. Hanna

2003 ◽  
Vol 11 (1-2) ◽  
pp. 169-181 ◽  
Author(s):  
Masaya Mukai ◽  
Tomoya Hinoki ◽  
Takayuki Tajima ◽  
Hisao Nakasaki ◽  
Shinkichi Sato ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document